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Malard et al. [1] reported their observation of an
inverse correlation between cyclosporine (CsA) con-
centrations within the first 2 weeks after hematopoietic
stem cell transplantation (HSCT) and the severity of
acute graft-versus-host disease (aGVHD). CsA was
given first as a continuous i.v. infusion and then orally
in patients able to receive oral medication. CsA con-
centrations are referred to as ‘‘trough’’ concentrations,
with no distinction made with respect to route of ad-
ministration (continuous i.v. infusion vs oral). The
proportions of patients receiving i.v. and oral doses
each week after HSCT are not stated.
When doses are given on an intermittent schedule,
trough drug concentrations are obtained at the end of
a dosing interval and before administration of the next
dose. In contrast, drug concentrations can be deter-
mined at any time during a continuous infusion.
They can be either steady-state or non–steady-state
concentrations, depending on how long the infusion
rate is maintained. Ideally, steady-state concentra-
tions, whether drawn at the end of a dosing interval
or during a continuous i.v. infusion, are used to de-
scribe the relationship between a drug concentration
and a clinical endpoint. In any case, drug concentra-
tions obtained during continuous i.v. infusion do not
meet the definition of a trough concentration.
In centers where CsA is given by intermittent i.v. in-
fusion, trough whole blood concentrations are used to
individualize doses. Similar to the findings of Malard
et al., we reported that in 87 children undergoing mye-
loablative HSCT, higher trough CsA concentrations
during the week before engraftment significantly re-
duced theoddsofdeveloping severe aGVHD(univariate
analysis, P 5 .0409; multivariate analysis adjusted for
type of HSCT, P5 .0454) [2]. The majority of the chil-
dren (84 of 87) received a bone marrow transplant, and
the median day of engraftment was day 118 (mean,
day 119.2; range, day 111 to day 135). Therefore,
for many children, the week before engraftment coin-
cided with the second week posttransplantation.
Malard et al. [1] raised the question of whether area
under the curve (AUC) rather than troughconcentration
might be a more effective parameter on which to base
CsA dosing. Concentrations determined at steady state
in patients receiving continuous CsA i.v. infusion can
be used to estimate theAUC.Determination ofAUCaf-
ter intermittent i.v. infusion traditionally requiresmulti-
ple concentration-time points obtained during the
dosing interval. We have developed a limited sampling
strategy for determining CsA AUC after a 2-hour CsA
Biol Blood Marrow Transplant 16:–867, 2010 867Letters to the Editorinfusion, and in so doing have observed poor correlation
(Spearman’s rho 5 0.457; P 5 .032) between the con-
centration obtained 12 hours after the start of the infu-
sion (trough concentration) and AUC [3,4].
We agree with Malard et al. that CsA concentra-
tion is an important predictor of aGVHD, that both
the magnitude of the CsA concentration and the
time relative to HSCT when it is achieved are impor-
tant in this regard, and that the usefulness of CsA AUC
as a predictor of aGVHD should be explored. How-
ever, the median weekly CsA concentrations for the
first month after HSCT presented by Malard et al. ap-
pear to represent a mix of steady-state and non–steady-
state concentrations obtained during continuous CsA
i.v. infusions and trough concentrations obtained dur-
ing oral dosing. Thus, it is not possible to fully appre-
ciate the target CsA concentrations proposed by these
investigators or their impact on aGVHD severity.
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